Log In
BCIQ
Print this Print this
 

SB-913

  Manage Alerts
Collapse Summary General Information
Company Sangamo BioSciences Inc.
DescriptionZFN-mediated genome editing that runs on the In Vivo Protein Replacement Platform (IVPRP)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis II (MPS II, Hunter syndrome)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today